論文

査読有り 筆頭著者 国際誌
2013年1月3日

Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience.

Blood
  • Hidehiro Itonaga
  • Hideki Tsushima
  • Jun Taguchi
  • Takuya Fukushima
  • Hiroaki Taniguchi
  • Shinya Sato
  • Koji Ando
  • Yasushi Sawayama
  • Emi Matsuo
  • Reishi Yamasaki
  • Yasuyuki Onimaru
  • Daisuke Imanishi
  • Yoshitaka Imaizumi
  • Shinichiro Yoshida
  • Tomoko Hata
  • Yukiyoshi Moriuchi
  • Naokuni Uike
  • Yasushi Miyazaki
  • 全て表示

121
1
開始ページ
219
終了ページ
25
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1182/blood-2012-07-444372

Adult T-cell leukemia/lymphoma (ATL) relapse is a serious therapeutic challenge after allogeneic hematopoietic stem cell transplantation (allo-SCT). In the present study, we retrospectively analyzed 35 patients who experienced progression of or relapsed persistent ATL after a first allo-SCT at 3 institutions in Nagasaki prefecture (Japan) between 1997 and 2010. Twenty-nine patients were treated by the withdrawal of immune suppressants as the initial intervention, which resulted in complete remission (CR) in 2 patients. As the second intervention, 9 patients went on to receive a combination of donor lymphocyte infusion and cytoreductive therapy and CR was achieved in 4 patients. Of 6 patients who had already had their immune suppressants discontinued before the relapse, 3 patients with local recurrence received local cytoreductive therapy as the initial treatment, which resulted in CR for more than 19 months. Donor lymphocyte infusion-induced remissions of ATL were durable, with 3 cases of long-term remission of more than 3 years and, interestingly, the emergence or progression of chronic GVHD was observed in all of these cases. For all 35 patients, overall survival after relapse was 19.3% at 3 years. The results of the present study suggest that induction of a graft-versus-ATL effect may be crucial to obtaining durable remission for ATL patients with relapse or progression after allo-SCT.

リンク情報
DOI
https://doi.org/10.1182/blood-2012-07-444372
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/23100309
ID情報
  • DOI : 10.1182/blood-2012-07-444372
  • PubMed ID : 23100309

エクスポート
BibTeX RIS